DIGEST

Summary

This episode covers significant developments in oncology and biotech finance, including Bristol Myers Squibb's notable partnership with Hengrui Pharma, Isomorphic Labs' recent funding milestone, breakthrough findings on Tamm-Horsfall protein for triple-negative breast cancer, and research on KMT2C and KMT2D mutation implications in cancer therapeutics. We also discuss advances in AI for integrating multi-omics data to personalize cancer treatment and Odyssey Therapeutics' IPO signals.